A new medical device has entered clinical practice following regulatory clearance in the United States. Emboline announced the first commercial use of its Emboliner Embolic Protection System on October 2, 2026. The procedures took place one day earlier at NewYork-Presbyterian/Columbia University Irving Medical Center. Physicians used the device during two transcatheter aortic valve replacement procedures. The milestone moves the privately held medical technology company’s product from regulatory clearance into commercial use.
Emboliner Brings Embolic Protection Into Heart Procedures
Transcatheter aortic valve replacement, commonly called TAVR, treats severe aortic valve disease without traditional open-heart surgery. However, particles of debris can be released during these procedures. They may travel through the bloodstream and potentially reach the brain or other organs. Emboliner is designed to capture and remove this material during the intervention. Its full-body Embolic Protection approach targets debris beyond the cerebral circulation.
The device received US Food and Drug Administration 510(k) clearance on September 8, 2026. This regulatory decision allows its commercial marketing for the specified indication in the United States. The company subsequently confirmed that the product was available for sale. Its first commercial procedures were performed by Dr. Tamim Nazif and his clinical team. The launch initially focuses on selected structural heart centres.
Clinical evidence also provides context for the commercial milestone. The PROTECT H2H trial compared Emboliner with the established Sentinel Cerebral Protection System. The study enrolled 522 patients undergoing TAVR. Published trial findings reported comparable 30-day primary outcomes between the two groups. Emboliner captured more debris particles during the procedures. However, greater debris capture does not automatically establish lower stroke rates or improved long-term outcomes.
For hospitals and interventional cardiologists, the introduction adds another Embolic Protection option during complex heart procedures. The device’s full-body design distinguishes its approach from systems focused on cerebral protection. Its real-world adoption will depend on clinical experience, physician assessment and further outcome data. The commercial launch also creates an opportunity to evaluate its performance beyond controlled clinical settings.
Led by President and CEO Scott Russell, Emboline is based in Santa Cruz, California. The company focuses on technologies intended to reduce embolic complications during cardiovascular interventions. Its latest milestone marks the beginning of broader US commercial introduction. Embolic Protection remains an important area of device development as clinicians seek ways to manage procedural risks during minimally invasive heart treatment.
